$CVRX News

CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026

CVRx Reports Q2 2026 Results: Full Earnings Call Transcript

CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026

CVRx To Present Barostim Data And Clinical Research At HFSA Annual Scientific Meeting 2026

CVRx Appoints John Landry as Chief Financial Officer

CVRx Appoints John Landry CFO, Effective Oct. 12, Succeeding Jared Oasheim

CVRx Responds to Letter from Pointillist Family Office

CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy

Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer

CVRx Shareholder Urges Board To Launch Sale Process To Unlock Barostim’s Strategic Value

Cantor Fitzgerald Maintains Overweight on CVRx, Lowers Price Target to $5

CVRx (CVRX) Q2 2026 Earnings Call Transcript

CVRx, Inc. (CVRX) Presents at Canaccord Genuity's 46th Annual Growth Conference - Slideshow

CVRx Announces Sales Leadership Transition

Lake Street Downgrades CVRx to Hold, Lowers Price Target to $3.5

CVRx, Inc. Q2 2026 Earnings Call Summary

CVRx, Inc. (CVRX) Q2 2026 Earnings Call Transcript

CVRx Inc (CVRX) (Q2 2026) Earnings Call Highlights: Sales Execution Challenges Offset Strong ...

CVRx (CVRX) Reports Q2 Loss, Beats Revenue Estimates

CVRx Q2 Earnings Call Highlights